- Previous Close
0.0000 - Open
0.2650 - Bid --
- Ask --
- Day's Range
0.2650 - 0.2650 - 52 Week Range
0.2650 - 0.6000 - Volume
200 - Avg. Volume
0 - Market Cap (intraday)
55.985M - Beta (5Y Monthly) -0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1800 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
www.oncopeptides.com/svRecent News: ONPPF
View MorePerformance Overview: ONPPF
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONPPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONPPF
View MoreValuation Measures
Market Cap
35.00M
Enterprise Value
29.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.43%
Return on Equity (ttm)
-512.51%
Revenue (ttm)
31.65M
Net Income Avi to Common (ttm)
-284.61M
Diluted EPS (ttm)
-0.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
178.54M
Total Debt/Equity (mrq)
224.55%
Levered Free Cash Flow (ttm)
-166.16M